Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.
You're using version {0} of the web browser {1}. This means that the content or functionality of our website may be limited or unavailable. We recommend that you upgrade your browser to optimise your experience of our website.
Clinical treatment of bladder cancer: An addition to Affibody-mediated tumor targeting
| Reference number | 2006-01797 |
| Coordinator | Haldex Holding AB - Haldex Holding AB |
| Funding from Vinnova | SEK 542 000 |
| Project duration | September 2006 - December 2007 |
| Status | Completed |
Last updated 25 November 2019
Reference number 2006-01797
